BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

NEW YORK, April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc ... diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. Read More

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

CloseCurlyDoubleQuote; CLARITY Phase 3 Study Topline Data Highlights: CLARITY is a Phase 3 multi-center ... For more information, visit: LENZ-tx.com. This press release contains forward-looking ... Read More

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics ... today announced details regarding the planned design of its upcoming TRANQUILITY In-Care Phase 3 trial to evaluate BXCL501, the company ... Read More

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq ... We anticipate several important milestones including Phase 3 data in major depressive disorder and the initiation of ... Read More

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO ... Therapeutics. “We are highly encouraged with the results announced today, and look forward to sharing additional data later ... Read More

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled ... Read More

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase ... the data referenced in this press release is derived ... Read More

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc, Nasdaq ... s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in ... Read More

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline ... We look forward to the topline data readouts from the Phase 2 studies in Huntington’s disease and Alzheimer ... Read More

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

The Company expects to generate additional Phase 3 efficacy and safety data in the TRANQUILITY In ... please visit bioxceltherapeutics.com. This press release includes “forward-looking ... Read More

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

Data from the paper are from a randomized, double-blind, placebo-controlled Phase 3 trial, evaluating the ... the National MS Society (NMSS). This press release contains "forward-looking ... Read More